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Abstract
Introduction—We aimed to investigate if cerebral amyloid angiopathy (CAA) is more frequent 
in genetically determined than in sporadic early onset forms of Alzheimer disease (EOAD).
Methods—Neuroimaging features of CAA, APOE, and cerebrospinal fluid-Aβ40 levels were 
studied in subjects with Down syndrome (DS, n=117), autosomal dominant AD (ADAD, n=29), 
sporadic EOAD (n=42), and healthy controls (n=68).
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Results—CAA was present in 31%, 38% and 12% of cognitively impaired DS, symptomatic 
ADAD, and sporadic EOAD subjects, and in 13% and 4% of cognitively unimpaired DS 
individuals and healthy controls, respectively. APOE-ε4 genotype was borderline significantly 
associated with CAA in sporadic EOAD (p=0.06), but not with DS or ADAD. There were no 
differences in Aβ40 levels between groups or between subjects with and without CAA.
Discussion—CAA is more frequently found in genetically determined AD than in sporadic 
EOAD. Cerebrospinal fluid-Aβ40 levels are not a useful biomarker for CAA in AD.
Keywords
Cerebral amyloid angiopathy; sporadic early onset Alzheimer disease; autosomal dominant 
Alzheimer disease; Down syndrome; neuroimaging; cerebrospinal fluid biomarkers
Introduction
Most cases of Alzheimer's disease are sporadic, and caused by complex interactions between 
genetic and environmental factors. In approximately 5% of cases, Alzheimer's disease can 
present clinically before the age of 65 (early-onset Alzheimer's disease-EOAD) [1]. These 
patients frequently present with non-amnestic phenotypes and faster clinical decline than 
older sporadic Alzheimer's disease cases [1]. In 0.1-0.5% of cases, Alzheimer's disease is 
transmitted with an autosomal dominant pattern of inheritance (ADAD) due to the presence 
of mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein 
(APP) genes [2]. Down syndrome (DS) is also recognized as a form of genetically 
determined AD, mainly caused by the APP gene triplication [2]. Despite the different 
genetic background, the Alzheimer's disease neuropathological findings in sporadic EOAD, 
ADAD and DS are very similar [3,4].
Cerebral Amyloid Angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage 
(ICH) in the elderly and is present in up to 90% of Alzheimer's disease brains at autopsy [3]. 
Previous neuropathological studies have suggested a more severe CAA in ADAD than in 
sporadic Alzheimer's disease [4]. CAA in some APP mutations or duplication carriers drives 
the clinical presentation [4], and is also consistently observed in subjects with DS [5]. The 
modified Boston criteria for CAA-related hemorrhage (mBCAA) have been validated to 
attribute in vivo an ICH to CAA based on several neuroimaging features, and are frequently 
used in clinical practice [6]. There are no previous studies systematically assessing the CAA 
neuroimaging features in DS and ADAD.
Aβ40 is the major form of Aβ deposited in the vessel walls in individuals with CAA. Low 
levels of Aβ40 and Aβ42 have been found in the CSF of subjects with sporadic CAA [7]. 
However, scarce and contradictory data are available about the CAA CSF biomarker profile 
in sporadic Alzheimer's disease patients [8–10], and no previous studies have assessed this 
profile in DS or ADAD. Moreover, the APOE-ε4 genotype is a risk factor for both sporadic 
Alzheimer's disease and sporadic CAA [11], as it increases Aβ deposition in both the 
parenchyma and blood vessels [12]. However, the effect of the APOE genotype in 
Alzheimer's disease dementia within DS and ADAD is controversial, and there are no 
studies assessing the influence of the APOE genotype on CAA in ADAD or DS [13].
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The differences in the CAA neuroimaging features and CSF biomarkers profile in the 
different forms of Alzheimer's disease are thus, not established. Our primary objective was 
to determine the CAA presence assessing the fulfillment of the mBCAA and the CSF Aβ40 
levels in three different Alzheimer's disease populations: DS, ADAD and EOAD. We 
hypothesized that patients with genetically determined Alzheimer's disease would have more 
CAA neuroimaging and biochemical features than EOAD.
Materials and methods
Study design and participants
A total of 256 subjects were recruited from 5 centers: Hospital of Sant Pau, Hospital Clínic 
de Barcelona, and Barcelona Down Medical Center in Barcelona, Spain; and the Sanders-
Brown Center on Aging in Kentucky and the Down Syndrome Biomarker Initiative (DSBI) 
project in San Diego, United States of America. Four study groups were evaluated: EOAD, 
ADAD, DS, and healthy controls (HC).
EOAD (N=42)—Patients were recruited at the Memory Unit of Hospital de Sant Pau from 
the Sant Pau Initiative on Neurodegeneration (Barcelona SPIN cohort) [14]. We used the 
International Working Group-2 diagnostic criteria for AD with in vivo evidence of AD based 
on CSF biomarkers [2]. This group included 19 individuals with prodromal AD (p-EOAD) 
and 23 subjects with probable AD dementia (d-EOAD).
ADAD (N=29)—Participants were recruited from the Genetic counseling program for 
familial dementias (PICOGEN) at the Hospital Clínic de Barcelona [15]. Fifteen 
symptomatic carriers (CDR≥ 0.5) carrying 9 different PSEN1 mutations (M139T, S169P, 
L173F, G209E, L235R, K239N, L282R, L286P, I439S) and one symptomatic carrier of the 
APP I716T mutation were included. The symptomatic carriers were further classified as 
prodromal ADAD (pAD-ADAD, n=5) and ADAD dementia (dADAD, n=11). Twelve pre-
symptomatic mutation carriers (CDR= 0) carrying 7 different PSEN1 mutations (M139T, 
S169P, L173F, R220G, K239N, L282R, I439S) and one pre-symptomatic carrier of APP 
I716T were labeled as asymptomatic ADAD. We used the IWG2 diagnostic criteria for AD 
[2].
DS (N=117)—Adults with DS were recruited from three centers, the Down Alzheimer 
Barcelona Neuroimaging Initiative (DABNI) in the Barcelona Down Medical Center [16]; 
the Sanders-Brown Center on Aging; and the DSBI pilot project [17]. Adapted 
neuropsychological batteries (detailed in the Appendix section), covering all cognitive 
domains classified DS subjects into “without cognitive decline” (asymptomatic DS, N=91), 
prodromal AD (pAD-DS, N=13), and AD dementia (dAD-DS, N=13). pAD-DS and dAD-
DS were also labeled as symptomatic DS.
Healthy controls (N=68)—Participants were recruited at Hospital de Sant Pau (n=60) and 
Hospital Clínic de Barcelona (n=8) enrolled among patients' caregivers. They did not have 
cognitive complaints, scored 0 on CDR, had normal neuropsychological evaluation, and 
normal core Alzheimer's disease CSF biomarkers [18,19].
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Procedures
Medical records were reviewed for potential confounders and effect modifiers: age, sex, and 
presence of arterial hypertension, neuropsychological information on disease severity 
(MMSE for EOAD and ADAD and the Cambridge Examination for mental Disorders of 
Older People with DS and Others with Intellectual Disabilities-Cognitive Scale - 
CAMCOG-DS scale for DS) were recorded and sent to the coordinating center (Hospital de 
Sant Pau) with the CSF biomarkers (Aβ42, Aβ40) and neuroimaging data.
The study was approved by the local Ethics Committees following the ethical standards 
recommended by the Helsinki Declaration. All participants and/or their caregivers gave their 
written informed consent.
Neuroimaging assessments
The inclusion criteria for all participants included a 1.5 or 3T MRI scan including T2*-GRE 
or SWI, axial fluid attenuated inversion recovery (FLAIR) and coronal T1-weighted 
sequences in the five centers involved GRE or SWI sequences were assessed for the 
presence of the main CAA neuroimaging features: localization and number of lobar 
microbleeds, presence of cortical superficial siderosis (cSS), and lobar ICH. We evaluated 
the fulfillment of mBCAA in all participants regardless of the age criterion included in the 
criteria set (>55 years) [6]. White matter hyperintensites (WMH) were semi-quantitatively 
assessed in FLAIR sequences according to the Fazekas score [20]. MTA was evaluated in 
coronal T1-weighted images trough the Scheltens scale [21]. MTA was scored bilaterally 
and the highest score was considered for the analyses.
The radiological evaluation was performed by two raters (either MCI or MB; neurologists 
with expertise in cognitive disorders and SG; neuroradiologist) blinded to the clinical data. 
Inter-rater reliability was above 90% and discrepancies within ratings were solved by 
consensus.
CSF biomarkers and APOE genotype
The inclusion criteria for EOAD and healthy controls included CSF data, but not for ADAD 
and DS. Details of analysis are described elsewhere [14,18]. In short, commercially available 
ELISA kits were used to determine CSF-Aβ40 and CSF-Aβ42 levels (Millipore and 
Fujirebio-Europe, respectively), following the manufacturers' recommendations.
APOE genotyping was performed by PCR amplification of the exon four fragment 
containing the two polymorphisms (rs429358 and rs7412) that encode the three common 
APOE isoforms. The following oligonucleotides: APOE-F: 5′-
ACTGGAGGAACAACTGACCC-3′ and APOE-R: 5′-CTGCCCATCTCCTCCATC-3′, 
were used and final PCR products were purified and Sanger sequenced using BigDye 
terminator chemistry (Applied Biosystems). Sequences were run on an Applied 
Biosystems® 3130 Genetic Analyzer and resulting elecropherograms were visually 
inspected using Sequencher (version 4.1, Gene Codes Corp.).
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Statistical analysis
Statistical analyses were performed with the Statistical Package for the Social Sciences v19 
software (IBM corp. http://www-01.ibm.com/software/es/analytics/spss/). The primary 
objectives of this study were to compare across groups the frequency of the mBCAA and the 
CSF-Aβ40 levels and were analyzed with the exact Fisher and Mann-Whitney test 
respectively.
The secondary objectives were to assess the white matter lesions measured by the Fazekas 
scale and the hippocampal atrophy measured by the Scheltens scale and were analyzed with 
the exact Fisher test. Spearman correlation coefficients were calculated between age, clinical 
stage, hippocampal atrophy and white matter lesions and the different study groups. With the 
purpose of improving the statistical power, prodromal and demented groups in EOAD, 
ADAD and DS were merged when analyzed. All significance tests were two-sided with the 
statistical significance set at 5%.
Results
Table 1 displays the demographics, clinical features, CSF data, and APOE genotype of the 
participants. CSF data were available in 71% (N=182) of the subjects (including all healthy 
controls and patients with EOAD). Symptomatic ADAD and symptomatic DS subjects were 
younger than patients with EOAD (48.4, 54.4, 61.1 years of age respectively; p<0.001).
The APOE-ε4 allele frequency was higher in EOAD than in any other group. However, no 
differences were observed between symptomatic or asymptomatic subjects within the 
ADAD or DS groups.
Table 2 shows the neuroimaging results across the different groups. The fulfillment of the 
mBCAA criteria was more frequent in symptomatic DS, 31% (N=8), and in symptomatic 
ADAD, 38% (N=6), than in EOAD 24% (N=19) (p=0.055 and 0.026 respectively). When 
present, the most frequent CAA neuroimaging features were lobar microbleeds in 91.2% 
(N=31), followed by cSS in 29.4% (N=10) and ICH in 8.8% (N=3). All three features were 
more frequent in the symptomatic than in asymptomatic subjects within all groups (Table 2).
The symptomatic ADAD and DS groups had a higher proportion of lobar microbleeds than 
the EOAD group (p=0.02, p=0.046 respectively). cSS and ICH were statistically associated 
(p=0.004). In those who had cSS, 20% (N=2) had also an ICH, and cSS was present in 67% 
(N=2) of those with ICH. Symptomatic DS had a higher proportion of subjects with cSS and 
lobar ICH than the EOAD group, but this difference did not reach statistical significance 
(p=0.056). The position of the mutation (pre or post codon 200) did not significantly impact 
the presence of lobar microbleeds in PSEN1 carriers (37 vs 25%, p=0.4). One of the 
asymptomatic ADAD subjects included in our study had a massive lobar ICH after 
recruitment into this study that lead to its dead in a stage of moderately severe dementia.
The mean time lag between MRI and CSF sampling was 5.3 months. Symptomatic 
participants had lower CSF-Aβ42 levels than asymptomatic subjects within all groups 
(Figure 1A). No significant differences were detected in CSF-Aβ40 levels between the 
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different groups or between symptomatic and asymptomatic subjects within each group 
(Figure 1B).
All EOAD patients fulfilling the mBCAA were APOE-ε4 carriers and the APOE-ε4 allele 
was significantly more frequent in EOAD subjects than in the symptomatic ADAD 
(p=0.015) or symptomatic DS (p=0.071) subjects fulfilling the mBCAA criteria. In sporadic 
EOAD, there was a trend for the association between mBCAA fulfillment and APOE-ε4 
genotype (p=0.06).
There were no differences in CSF-Aβ40 levels between those subjects who fulfilled the 
mBCAA criteria and those who did not (or the presence of lobar microbleeds, cSS, or ICH) 
in any group.
Symptomatic subjects presented higher Fazekas scores than asymptomatic subjects in all 
groups: EOAD patients had higher Fazekas scores than healthy controls (p<0.001); 
symptomatic ADAD higher than asymptomatic ADAD (p=0.022) or HC (p=0.05); and 
symptomatic DS higher than asymptomatic DS (p=0.011) and healthy controls (p<0.001) 
(Figure 2 and table 2).
There was a significant positive correlation between age and Fazekas score in the whole 
sample (r=0.337, p<0.001), in ADAD (r=0.407, p=0.031) and in DS (r=0.506, p=0.000) 
groups. This correlation was also found in asymptomatic DS (r=0.495, p<0.001) and in 
healthy controls (r=0.323, p=0.007) (Figure 3).
Age positively correlated with Scheltens scores in the whole sample (r=0.229, p<0.001), 
healthy controls (r=0.276, p=0.023), ADAD (r=0.412, p=0.027), asymptomatic DS (r=0.341, 
p=0.001), and symptomatic DS (r=0.431, p=0.023). The Scheltens scores increased from 
asymptomatic to symptomatic subjects within each group. Symptomatic DS patients 
presented higher MTA scores than EOAD and symptomatic ADAD patients (p<0.001 in 
each comparison) and asymptomatic DS subjects higher than HC (p<0.001). There were no 
differences in Scheltens scores between EOAD and symptomatic ADAD.
Discussion
We found that DS and ADAD have a more severe CAA than EOAD as measured by the 
mBCAA criteria, but CAA did not impact the CSF-Aβ40 levels. The APOE-ε4 allele might 
be associated with CAA in EOAD, but does not seem to have an effect in DS or ADAD.
There are previous studies assessing the prevalence of lobar microbleeds in ADAD and 
EOAD [22] [23,24], but, to our knowledge, none has specifically assessed and compared the 
mBCAA between the different AD populations. The mBCAA were more frequent in DS and 
ADAD, suggesting a more severe CAA, as shown in pathological studies [5,25]. The most 
frequent CAA neuroimaging feature was the presence of lobar microbleeds, as previously 
described [26]. The frequency of lobar microbleeds in ADAD (and healthy controls) was in 
agreement with the literature (ranging from 25% to 66%) [23,24][26], but we found a lower 
frequency of lobar microbleeds in EOAD (9.5%) than that reported in late onset AD 
(20-30%) [27]. Age might be responsible for this difference. There are no previous studies 
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assessing the mBCAA criteria or any of its component neuroimaging features in DS. CAA is 
also consistently observed in DS pathological studies [5,28], but it had been proposed that 
other genetic factors in DS might protect these subjects from the ICH [29]. We found 38.5% 
of frequency for lobar microbleeds in symptomatic DS and, more importantly, a frequency 
of 15.4% for ICH. While this is lower than the reported 30% prevalence for symptomatic 
ICH in non-trisomic APP duplication carriers, it is well above the 3%-3.8% figure for 
symptomatic ICH in DS reported in the same study [29]. This discrepancy might be 
explained because many non-fatal ICH might be unnoticed in DS with AD. Of note, both 
subjects with DS and ICH on the MRI did not present with ICH-related clinical symptoms.
A significant percentage of symptomatic subjects, nonetheless, did not meet the mBCAA 
and were free of the CAA associated neuroimaging features. This is in contrast with 
pathological studies, where CAA is found in up to 90% of AD brains, suggesting that the 
available MRI sequences only identify a subset of AD-CAA subjects [23]. The CAA 
neuroimaging features might thus detect only the most severe cases or, alternatively, they 
might select different subgroups of patients [23]. In this respect, cSS, although less frequent 
than lobar microbleeds, was strongly associated with lobar ICH. cSS might be a particular 
important marker for severe CAA in AD, as it has been suggested in sporadic CAA [7]. 
More work in longitudinal studies is needed to confirm the higher risk conferred by cSS for 
future ICH and cognitive decline.
We also assessed other neuroimaging features associated with CAA, but not included in the 
mBCAA criteria. Both WMH and MTA are increasingly recognized as core Alzheimer's 
disease features and as a manifestation of CAA [30]. We found a gradient in WMH 
extension in all groups [31], but we also found more extended WMH in those subjects 
fulfilling the mBCAA criteria. WMH also increased with age and in relation with vascular 
risk factors. We found this correlation also in healthy controls, even though they all had 
normal core Alzheimer's disease CSF biomarkers and low prevalence of HBP. However, we 
found a strong correlation between age and WMH in asymptomatic DS despite their younger 
mean age. This correlation supports the relationship between amyloid deposition and WMH. 
Not surprisingly, the Scheltens scores increased with symptom severity in all AD 
populations. Hippocampal atrophy, however, was more severe in DS, even in asymptomatic 
DS individuals. These results are in agreement with the notion that individuals with DS have 
smaller hippocampal size from birth, but also show atrophy when Alzheimer's disease 
develops [17].
Decreased CSF-Aβ40 levels might differentiate sporadic CAA from healthy controls and 
Alzheimer's disease cases [7]. In our study, nevertheless, CSF-Aβ40 levels did not 
discriminate CAA neuroimaging features in any group. This finding could be influenced by 
the fact that amyloid vascular burden in CAA in ADAD and DS contains not just Aβ40, but 
also Aβ42. It is difficult to sort out the contribution of vascular Aβ42 deposition from 
parenchymal plaque deposition except with neuropathological analysis of the post-mortem 
brain, which was not available in this study [32,33].
To our knowledge, there are only two studies that determine CSF-Aβ40 in subjects with 
Alzheimer's disease with and without lobar microbleeds and show conflicting findings 
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[9,10]. In any case, our results suggest that CSF-Aβ40 levels are not a sensitive biomarker to 
detect CAA in the context of an Alzheimer's disease process.
The APOE-ε4 allele confers a higher risk for CAA in the general population and in 
Alzheimer's disease [11,12]. We also found a trend for an association between APOE-ε4 
genotype and CAA in sporadic early onset Alzheimer's disease. Furthermore, all EOAD 
subjects with CAA neuroimaging features were APOE-ε4 carriers. We did not find this 
relationship in ADAD or DS. The APOE-ε4 genotype might be thus associated with CAA in 
EOAD, but not in DS or ADAD. In ADAD and DS, other genetic factors, such as the type or 
position of the causing mutation in ADAD, might be more important in predicting CAA [4].
Our findings have potential clinical implications. The mBCAA criteria have not been 
validated in patients <55 years of age. We consider that, at least in ADAD and DS, age 
should not be an essential requirement for CAA diagnosis. Our results also have substantial 
implications in Alzheimer's disease clinical trials given the relationship between CAA and 
amyloid-related neuroimaging abnormalities (ARIA). Vascular amyloid may be a 
pathophysiological mechanism for ARIA [34,35] and recent studies have shown that after 
Aβ immunotherapy there is an increase in CAA severity and an increase in lobar 
microbleeds associated with removal of plaques [36]. Trials targeting Aβ commonly use 
lobar microbleeds and APOE genotype to stratify subjects [37]. However, there are no 
available data on the relationship of CAA neuroimaging abnormalities (and APOE) and 
ARIA in the setting of amyloid-lowering therapy in ADAD and DS. Our data emphasize 
heterogeneity in prevalence and possibly etiology for CAA, therefore, the recommendations 
on the exclusions for presence of baseline ARIA-H (microbleeds or hemosiderosis) from 
sporadic Alzheimer's disease should be taken with caution. On the other hand, the APOE-ε4 
genotype is also commonly used to stratify participants given its influence on ARIA [37], 
however this strategy might not be as important in ADAD or DS. Finally, our data also 
suggest that the CSF-Aβ40 levels will not be a useful biomarker in these trials.
The higher prevalence of CAA in ADAD and DS might play a role in the conversion to 
clinical dementia. In sporadic Alzheimer's disease, CAA is an independent contributor to 
cognitive impairment and can worsen the severity of cognitive dysfunction [38]. Future 
longitudinal studies are needed to assess the CAA contribution to cognitive impairment in 
ADAD and DS.
The main strengths of the present study are the relatively large sample size of different rare 
populations, such as ADAD and DS, as well as the confirmation of the clinical diagnosis 
with genetics or CSF biomarkers. The study has some limitations. The use of two different 
imaging techniques is an important limitation when estimating the real prevalence of lobar 
microbleeds. SWI has a higher sensitivity for hemosiderin, detecting up to 50% more lobar 
microbleeds than conventional T2*GRE [39]. However, in our study the ADAD group was 
exclusively investigated using T2*GRE leading to a possible underestimation of the CAA 
neuroimaging features in these subjects. Finally, most of the EOAD patients were at a stage 
of mild dementia and we lack neuropathological data.
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In conclusion, the CAA-associated neuroimaging features are more frequent in adults with 
DS and in patients with ADAD than in those with EOAD suggesting a more severe CAA 
pathology. Our study also shows that the CSF-Aβ40 levels are not a reliable biomarker for 
CAA and that the risk factors for CAA (such as the APOE-ε4 genotype) might be different 
in EOAD and genetically determined Alzheimer's disease. These findings should be taken 
into account in the design of clinical trials with anti-amyloid therapies in people with ADAD 
or DS.
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Appendix
Neuropsychological batteries assessed in the Down syndrome group.
Each participant received an annual physical and neurological examination. Diagnostic was 
established after a clinical consensus performed by the clinical neurologist and the 
neuropsychologist.
- Neuropsychological battery from the Down Alzheimer Barcelona Neuroimaging 
Initiative (DABNI), Spain.
- Kauffman Brief Intelligence Test
- CAMDEX-DS (informant interview) and CAMCOG-DS (subject 
cognitive assessment)
- Clued recall test (Free and cued immediate and delayed recall)
- Digit span (forward/ backward)
- Picture cancellation task (Devenny)
- Barcelona Test (assessment of limb apràxia-pantomime of intransitive 
gestures)
- Cats and dogs tests
- Verbal fluency (animals)
- Abstract thinking (Barcelona test)
Carmona-Iragui et al. Page 9
Alzheimers Dement. Author manuscript; available in PMC 2018 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
- Mental State examination- DS (MEC-DS), screening instrument, not 
validated
- Neuropsychiatric inventory (12 item NPI)
- Fundació Catalana Sindrome de Down Functional Scale, not validated
- Dementia questionnaire for people with intellectual disabilities (DMR)
- Neuropsychological battery from the Sanders-Brown Center on Aging in 
Kentucky, USA.
- Kauffman Brief Intelligence Test
- Severe Impairment Battery
- Brief Praxis Test
- Fuld Object Memory Evaluation
- Peabody Picture Vocabulary Test (4th ed.)
- Children's Memory Scale: Dot Locations
- Category verbal fluency
- Beery Visual Motor Integration
- Neuropsychiatric inventory (NPI)
- WISC-R Block Design
- Vineland Adaptive Behavior Scale
- Behavioral Rating of Executive Functions (BRIEF)
- Adaptive Behavior Assessment System (ABAS)
- Dementia Questionnaire for people with intellectual disabilities 
(DMR)
- Neuropsychological battery from the Down Syndrome Biomarker Initiative 
(DSBI) project in San Diego, USA is detailed in Rafii et al. Front Behav 
Neurosci. 2015, 14;9:239.
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Figure 1. CSF biomarker levels in the clinical groups, according to modified Boston criteria for 
CAA (cBCAA)
Box plot displaying the distribution of CSF-Aβ42 (A) and CSF-Aβ40 (B) from healthy 
controls, sporadic EOAD, asymptomatic ADAD (aADAD), symptomatic ADAD (sADAD), 
asymptomatic DS (aDS), and symptomatic DS (sDS). Subgroups in blue represent those 
subjects who do not fulfill cBCAA, subgroups coloured in green do fulfill cBCAA for 
possible or probable CAA.
No differences in levels of CSF-Aβ42 or in CSF- Aβ40 were detected between subjects that 
fulfilled cBCAA and those who did not within each clinical group.
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Figure 2. Proportion of subjects in each group according modified Boston criteria, Fazekas score, 
and medial temporal lobe atrophy
Frequency bar graph showing: A) modified Boston criteria fulfillment, B) Fazekas score 
and, C) MTA score of each clinical group. Healthy controls and sporadic AD in the first row, 
ADAD in the second row, DS in the third row.
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Figure 3. Proportion of subjects according to Fazekas score by range of age
The frequency bar graphs showing the percentage of subjects with each Fazekas categories 
by age in: A) Healthy controls and, B) asymptomatic Down syndrome subjects.
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